Otezla (apremilast) is Celgene's attempt to break into the immunology field currently dominated by the TNF blocker drugs, led by AbbVie's Humira. The oral treatment has a novel mechanism ...
The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...
The Psoriatic Arthritis Long-t erm Assessment of Clinical Efficacy (PALACE) trial programme found Otezla to be superior to placebo but "compared with TNF-alpha inhibitors, apremilast was the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback